QANDLI DIABETDA GLYUKOZANI NAZORAT QILISHNING ZAMONAVIY YONDASHUVLARI
Keywords:
Qandli diabet, glyukozani nazorat qilish, metformin, GLP-1 agonistlari, SGLT2 inhibitörlari, insulin terapiyasi, orforglipron, sun’iy intellekt.Abstract
Ushbu maqolada qandli diabetda glyukozani nazorat qilishning
zamonaviy farmakologik yondashuvlari tahlil qilingan. Metformin, GLP-1 retseptor
agonistlari, SGLT2 ingibitörlari, DPP-4 ingibitörlari va insulin terapiyasining
samaradorligi, xavfsizligi va klinik qo‘llanilishi yoritilgan. Shuningdek, yangi dorivor
vositalar, masalan, orforglipron va sun’iy intellekt asosidagi insulin yetkazib berish
tizimlari haqida ma’lumot berilgan. Maqola qandli diabetni davolashda individual
yondashuvning ahamiyatini ta’kidlaydi.
References
1. American Diabetes Association. "9. Pharmacologic Approaches to Glycemic
Treatment: Standards of Medical Care in Diabetes—2020." Diabetes Care, 2020;
43(suppl 1): S98–S110.
2. Nauck MA, Weinstock RS, Umpierrez GE, et al. "Efficacy and safety of dulaglutide
versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial
(AWARD-5)." Diabetes Care, 2014; 37(8): 2149–2158.
3. Zinman B, Wanner C, Lachin JM, et al. "Empagliflozin, cardiovascular outcomes,
and mortality in type 2 diabetes." New England Journal of Medicine, 2015; 373(22):
2117–2128.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. "Liraglutide and cardiovascular
outcomes in type 2 diabetes." New England Journal of Medicine, 2016; 375(4): 311
322.
